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Abstract
Introduction: Identifying ankylosing spondylitis (AS) patients who are likely to benefit from tumor necrosis factor-
alpha (TNF-a) blocking therapy is important, especially in view of the costs and potential side effects of these
agents. Recently, the AS Disease Activity Score (ASDAS) has been developed to assess both subjective and
objective aspects of AS disease activity. However, data about the predictive value of the ASDAS with respect to
clinical response to TNF-a blocking therapy are lacking. The aim of the present study was to identify baseline
predictors of response and discontinuation of TNF-a blocking therapy in AS patients in daily clinical practice.
Methods: AS outpatients who started TNF-a blocking therapy were included in the Groningen Leeuwarden
Ankylosing Spondylitis (GLAS) study, an ongoing prospective longitudinal observational cohort study with follow-
up visits according to a fixed protocol. For the present analysis, patients were excluded if they had previously
received anti-TNF-a treatment. Predictor analyses of response and treatment discontinuation were performed using
logistic and Cox regression models, respectively.
Results: Between November 2004 and April 2010, 220 patients started treatment with infliximab (n = 32),
etanercept (n = 137), or adalimumab (n = 51). At three and six months, 68% and 63% of patients were
Assessments in Ankylosing Spondylitis (ASAS)20 responders, 49% and 46% ASAS40 responders, and 49% and 50%
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)50 responders, respectively. Baseline predictors of
response were younger age, male gender, higher ASDAS score, higher erythrocyte sedimentation rate (ESR) level,
higher C-reactive protein (CRP) level, presence of peripheral arthritis, higher patient’s global assessment of disease
activity, and lower modified Schober test. In August 2010, 64% of patients were still using their TNF-a blocking
agent with a median follow-up of 33.1 months (range 2.4 to 68.2). Baseline predictors of discontinuation of TNF-a
blocking therapy were female gender, absence of peripheral arthritis, higher BASDAI, lower ESR level, and lower
CRP level.
Conclusions: Besides younger age and male gender, objective variables such as higher inflammatory markers or
ASDAS score were identified as independent baseline predictors of response and/or continuation of TNF-a
blocking therapy. In contrast, higher baseline BASDAI score was independently associated with treatment
discontinuation. Based on these results, it seems clinically relevant to include more objective variables in the
evaluation of anti-TNF-a treatment.
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Randomized controlled trials (RCTs) have demonstrated
that the tumor necrosis factor alpha (TNF-a) blocking
agents infliximab, etanercept, and adalimumab are effec-
tive in the treatment of Ankylosing Spondylitis (AS).
However, a significant proportion of patients has to
withdraw from TNF-a blocking therapy due to ineffi-
cacy or adverse events [1-3]. Identifying patients who
are likely to benefit from TNF-a blocking therapy is
important, especially in view of the costs and potential
side effects of these agents.
Several studies using clinical data from RCTs have
focused on the identification of predictors of response
to anti-TNF-a treatment in AS [4-6]. However, many
patients who are treated with TNF-a blocking therapy
in daily clinical practice would have been excluded in
RCTs. Until now, three population based registries have
investigated predictors of response and/or continuation
of TNF-a blocking therapy. These registries showed that
raised inflammatory markers, lower Bath Ankylosing
Spondylitis Functional Index (BASFI), and younger age
at baseline were associated with clinical response [7,8],
whereas male gender, raised inflammatory markers, low
visual analogue scale (VAS) fatigue, and presence of per-
ipheral arthritis were baseline predictors of longer drug
survival [7,9].
Disease activity in AS encompasses a wide range of
concepts and is therefore difficult to measure. Recently,
the Ankylosing Spondylitis Disease Activity Score
(ASDAS) has been developed [10,11]. This new index is
a composite score of patient-reported measures and
acute phase reactants developed in order to capture
both subjective and objective aspects of AS disease
activity. Currently, information about the predictive
value of the ASDAS with respect to response to TNF-a
blocking therapy or drug survival is lacking due to the
absence of ASDAS data in previous studies. The aim of
the present study was to identify baseline predictors of
response and discontinuation of TNF-a blocking ther-
apy in AS patients in daily clinical practice.
Materials and methods
Patients
Since 2004 AS outpatients with active disease, who
started treatment with the TNF-a blocking agents inflix-
imab, etanercept, or adalimumab at the Medical Center
Leeuwarden (MCL) and the University Medical Center
Groningen (UMCG), were included in the Groningen
Leeuwarden Ankylosing Spondylitis (GLAS) study, an
ongoing prospective longitudinal observational cohort
study with follow-up visits according to a fixed protocol.
All patients were over 18 years of age, fulfilled the mod-
ified New York criteria for AS or the Assessments in
Ankylosing Spondylitis (ASAS) criteria for axial
spondyloarthritis including MRI [12], and started anti-
TNF-a treatment because of active disease according to
the ASAS consensus statement [13]. For the present
analysis, patients were excluded if they had previously
received anti-TNF-a treatment. Infliximab (5 mg/kg)
was given intravenously at zero, two and six weeks and
then every eight weeks. In case of inadequate response,
the frequency of infliximab treatment was raised to
every six weeks. Etanercept was administered as a sub-
cutaneous injection once (50 mg) or twice (25 mg) a
week. Adalimumab (40 mg) was administered as a sub-
cutaneous injection on alternate weeks. In the first years
of this study, patients were treated with either infliximab
or etanercept since adalimumab was only registered in
t h eN e t h e r l a n d ss i n c e2 0 0 6 .T h ec h o i c eo ft h eT N F - a
blocking agent was based on the judgment of the treat-
ing rheumatologist (chiefly) and/or the specific prefer-
ence of the patient. Patients were allowed to receive
concomitant medication as usual in daily clinical prac-
tice. The study was approved by the local ethics com-
mittees of the UMCG and MCL and all patients
provided written informed consent according to the
Declaration of Helsinki to participate in this study.
Clinical assessments
Patients were evaluated at baseline, after three and six
months of anti-TNF-a treatment, and then every six
months. Disease activity was assessed using the Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI;
on a scale of 0 to 10) [14], physician’s and patient’s glo-
bal assessment of disease activity (GDA; on a scale of 0
to 10), erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), and ASDAS calculated from BASDAI
questions 2, 3, and 6, patient’s GDA, and CRP [10,11].
Physical function was assessed using BASFI (on a scale
of 0 to 10) [15]. Spinal mobility assessments included
chest expansion, modified Schober test, occiput to wall
distance, and lateral lumbar flexion (left and right). Per-
ipheral arthritis was defined as at least one swollen joint
(excluding the hip) at baseline.
Response
At every visit, continuation of treatment was based on a
decrease in BASDAI, amounting to at least 50% (BAS-
DAI50 response) or two units compared with baseline,
and/or expert opinion in favor of treatment continua-
tion. The ASAS20 and ASAS40 response criteria have
been developed for defining treatment response in clini-
cal trials. ASAS20 response was defined as an improve-
ment of at least 20% and absolute improvement of at
least one unit (on a scale of 0 to 10) compared with
baseline in three or more of the four domains: physical
function (BASFI), pain, patient’s GDA, and inflammation
(mean from BASDAI questions 5 and 6), with no
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ASAS40 response was defined as an improvement of at
least 40% and an absolute improvement of at least two
units compared with baseline in three or more of the
four domains, with no worsening at all in the remaining
domain [12,16]. In the present analysis, the ASAS20,
ASAS40, and BASDAI50 response criteria were used to
define treatment response. Patients who did not respond
to TNF-a blocking therapy in the first three months
were classified as primary non-responders and patients
who lost their initial clinical response as secondary non-
responders.
Antibody assessment
Antibodies to TNF-a blocking agents were measured in
patients who discontinued infliximab or adalimumab
treatment due to inefficacy. Antibodies were detected by
radioimmunoassay (RIA) as described in detail previously
[17,18]. The assay measures specific high-avidity IgG
antibodies to infliximab or adalimumab by an antigen-
binding test. In short, serum (1 μl/test) was pre-incu-
bated with Sepharose-immobilized protein A (1 mg/test;
Pharmacia, Uppsala, Sweden) in Freeze buffer (Sanquin,
Amsterdam, The Netherlands). Non-bound serum com-
ponents were removed by washing before 50 μl
125I-radi-
olabeled F(ab)’2 fragment of infliximab or adalimumab
was added. After overnight incubation, non-bound radi-
olabel was washed away and Sepharose-bound radioactiv-
ity was measured. Test results were converted into
arbitrary units per milliliter (AU/ml) by comparison with
dilutions of a reference serum. The reference value was
set at 12 AU/ml, as derived from 100 healthy donors.
Statistical analysis
Statistical analysis was performed with SPSS 16.0 soft-
ware (SPSS, Chicago, IL, USA). Results were expressed
as mean ± SD or median (range) for normally and non-
normally distributed data, respectively. The Independent
Samples T test and Mann-Whitney U test were used to
compare differences between groups. The Chi-Square
test and Fisher Exact test were used to compare percen-
tages between groups. Predictor analyses of ASAS20,
ASAS40, and BASDAI50 response (yes/no) were per-
formed using binary logistic regression. Predictor analy-
sis of time to discontinuation of TNF-a blocking
therapy (yes/no) was performed using Cox regression.
Multivariate analysis was performed with conditional
stepwise forward inclusion of predictors that had a P-
value ≤0.3 in the univariate analysis. P-values < 0.05
were considered statistically significant.
Results
Between November 2004 and April 2010, a total of 220
patients (MCL: n = 163; UMCG: n =5 7 )s t a r t e d
treatment with a first TNF-a blocking agent; 32 receiv-
ing infliximab, 137 etanercept, and 51 adalimumab.
Mean age of all patients was 42.9 years (SD ± 11.9),
median disease duration was 15 years (range 1 to 53),
and 69% were male. The three treatment groups were
comparable for age, gender, HLA-B27 status, BASDAI,
ASDAS, patient’s GDA, CRP, ESR, concomitant medica-
tion, and presence of peripheral arthritis at baseline. In
the infliximab group, time since diagnosis was signifi-
cantly longer, the percentage of patients with a history
of inflammatory bowel disease (IBD) was significantly
higher, and occiput to wall distance was significantly lar-
ger compared to the etanercept and adalimumab groups.
In the adalimumab group, the percentage of patients
with a history of uveitis and physician’sG D Aw e r es i g -
nificantly lower and chest expansion was significantly
higher compared to the infliximab and/or etanercept
group (Table 1).
ASAS20 response
The percentage of ASAS20 responders to TNF-a block-
ing therapy was 68% and 63% at three and six months,
respectively. No significant differences were found in the
percentage of ASAS20 responders between the three
TNF-a blocking agents at three or six months (P =
0.297 and P = 0.128, respectively) (Table 2).
Results of univariate and multivariate logistic regres-
sion analysis for ASAS20 response at three and six
months of anti-TNF-a treatment are presented in
Tables 3 and 4, respectively. Male gender (OR: 2.166)
was identified as a significant baseline predictor of
ASAS20 response in univariate logistic regression analy-
sis. Therefore, variables that significantly differed
between men and women at baseline were included in
multivariate analysis: age, patient’sG D A ,E S R ,c h e s t
expansion, and occiput to wall distance. Multivariate
logistic regression analysis showed that younger age
(OR: 0.972), male gender (OR: 3.151), and higher ESR
level (OR: 1.023) or alternatively, higher CRP level (OR:
1.024) or higher ASDAS score (OR: 1.728), were inde-
pendent baseline predictors of ASAS20 response at
three months of anti-TNF-a treatment (Table 3).
At six months of anti-TNF-a treatment, younger age
(OR: 0.960), male gender (OR: 2.991), and higher
ASDAS score (OR: 1.573) or alternatively, presence of
peripheral arthritis (OR: 2.518) and higher patient’s
GDA (OR: 1.173), were independent baseline predictors
of ASAS20 response (Table 4).
ASAS40 response
The percentage of ASAS40 responders to TNF-a block-
ing therapy was 49% and 46% at three and six months,
respectively. No significant differences were found in the
percentage of responders between the three TNF-a
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= 0.421, respectively) (Table 2).
Multivariate logistic regression analysis showed that
younger age (OR: 0.970, 95% CI: 0.946 to 0.994) was the
only independent baseline predictor of ASAS40 response
at three months of anti-TNF-a treatment.
At six months of anti-TNF-a treatment, younger age
(OR: 0.961, 95% CI: 0.935 to 0.987), male gender (OR:
2.488, 95% CI: 1.235 to 5.014), and higher patient’s
GDA (OR: 1.258, 95% CI: 1.067 to 1.483) or alterna-
tively, higher ASDAS score (OR: 1.721, 95% CI: 1.159 to
2.555), were independent baseline predictors of ASAS40
response.
BASDAI50 response
The percentage of BASDAI50 responders to TNF-a
blocking therapy was 49% and 50% at three and six
months, respectively. No significant differences were
found in the percentage of responders between the
three TNF-a blocking agents at three or six months (P
= 0.358 and P = 0.866, respectively) (Table 2).
Multivariate logistic regression analysis showed that
younger age (OR: 0.975, 95% CI: 0.951 to 0.999), male
gender (OR: 2.572, 95% CI: 1.346 to 4.913), and higher
CRP level (OR: 1.025, 95% CI: 1.008 to 1.042) or alter-
natively, higher ESR level (OR: 1.026, 95% CI: 1.009 to
1.042), were independent baseline predictors of BAS-
DAI50 response at three months of anti-TNF-a
treatment.
At six months of anti-TNF-a treatment, younger age
(OR: 0.957, 95% CI: 0.929 to 0.985), male gender (OR:
2.598, 95% CI: 1.302 to 5.186), presence of peripheral
arthritis (OR: 4.991, 95% CI: 2.054 to 12.124), and lower
modified Schober test (OR: 0.751, 95% CI: 0.610 to
0.924) were independent baseline predictors of BAS-
DAI50 response.
Table 1 Baseline characteristics of the AS study population
Total IFX ETA ADA
Number of patients 220 32 137 51
Age (yrs) 42.9 ± 11.9 45.8 ± 10.1 41.9 ± 11.6 43.7 ± 13.3
Gender (male) (n, %) 152 (69) 20 (63) 96 (70) 36 (71)
Duration of symptoms (yrs) 15 (1 to 53) 21 (2 to 49) 15 (1 to 47) 11 (1 to 53)
Time since diagnosis (yrs) 7 (0 to 45) 16 (0 to 35)* 7 (0 to 44) 6 (0 to 45)
HLA-B27+ (n, %) 174 (81) 24 (75) 108 (82) 42 (82)
History of IBD (n, %) 20 (9) 8 (26)† 7 (5) 4 (8)
History of uveitis (n, %) 64 (29) 13 (40) 44 (32) 7 (14)‡
History of psoriasis (n, %) 13 (6) 3 (9) 8 (6) 13 (6)
Peripheral arthritis (n, %) 37 (17) 5 (16) 27 (20) 5 (10)
Current NSAID use (n, %) 158 (72) 24 (75) 102 (75) 32 (63)
Current DMARD use (n, %) 45 (21) 10 (31) 28 (20) 7 (14)
BASDAI (range 0 to 10) 6.1 ± 1.7 6.1 ± 1.4 6.2 ± 1.7 5.9 ± 1.7
ASDAS 3.8 ± 0.8 3.8 ± 0.6 3.8 ± 0.8 3.7 ± 0.9
Physician’s GDA (range 0-10) 5 (0 to 9) 5 (0 to 8) 5 (0 to 9) 3 (0 to 9)‡
Patient’s GDA (range 0 to 10) 7 (1 to 10) 6 (1 to 9) 7 (1 to 10) 6 (1 to 10)
ESR (mm/h) 21 (2 to 101) 24 (2 to 90) 20 (2 to 101) 23 (2 to 74)
CRP (mg/l) 13 (2 to 99) 15 (2 to 74) 12 (2 to 99) 14 (2 to 92)
BASFI (range 0 to 10) 6.1 (0.3 to 9.7) 6.3 (1.9 to 9.6) 5.9 (0.3 to 9.7) 6.3 (0.4 to 9.5)
Chest expansion (cm) 3.0 (0.5 to 43.0) 2.5 (0.5 to 7.0) 3.0 (0.5 to 22.0) 3.5 (0.0 to 43.0)§
Modified Schober test (cm) 2.9 (0.0 to 7.0) 2.4 (0.5 to 6.0) 2.8 (0.1 to 7.0) 3.2 (0.0 to 5.5)
Occiput to wall distance (cm) 4.9 (0.0 to 34.5) 9.0 (0.0 to 26.0)^ 4.5 (0.0 to 34.5) 3.5 (0.0 to 30.0)
Lateral lumbar flexion L (cm) 8.0 (0.0 to 30.0) 7.0 (2.0 to 15.0) 9.0 (0.0 to 30.0) 8.0 (1.0 to 20.5)
Lateral lumbar flexion R (cm) 8.0 (0.0 to 29.0) 8.0 (0.5 to 17.0) 8.0 (0.0 to 29.0) 7.5 (1.0 to 20.0)
Values are mean ± SD or median (range) unless otherwise indicated.
AS, Ankylosing Spondylitis; IFX, infliximab; ETA, etanercept; ADA, adalimumab; HLA-B27+, human leukocyte antigen B27 positive; IBD, inflammatory bowel disease;
NSAID, non-steroidal anti-inflammatory drug; DMARD, disease-modifying antirheumatic drug; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS,
Ankylosing Spondylitis Disease Activity Score; GDA, global disease activity; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASFI, Bath Ankylosing
Spondylitis Functional Index; L, left; R, right.
* P < 0.05 compared to ETA group and P = 0.052 compared to ADA group.
† P < 0.05 compared to ETA group and P = 0.050 compared to ADA group.
‡ P < 0.05 compared to IFX and ETA groups.
§ P < 0.05 compared to ETA group.
^ P < 0.05 compared to ETA and ADA groups.
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In August 2010, 141 (64%) patients were still using their
TNF-a blocking agent with a median follow-up of 33.1
months (range 2.4 to 68.2). The remaining 79 (36%)
patients discontinued TNF-a blocking therapy after med-
ian treatment duration of 7.0 months (range 0.2 to 55.6).
Reasons for discontinuation of TNF-a blocking therapy
were inefficacy (n = 40, 51%), adverse events (n =2 1 ,
27%: infection (n = 8); allergic reaction (n = 4); diarrhea
or IBD (n = 5); cardio-vascular disease (n = 2); demyeliza-
tion problems (n = 1); bladder cancer (n = 1)), both inef-
ficacy and adverse events (n =8 ,1 0 % :r e c u r r e n t
infections (n = 3); allergic reaction (n = 1); diarrhea or
IBD (n = 2); uveitis (n = 1); malaise (n = 1)), or other rea-
sons (n = 10, 13%: good initial response, own choice (n =
3); pregnancy wish (n = 5); lost to follow up (n = 2)).
Antibodies to TNF-a blocking agents were measured
in patients who discontinued infliximab (n = 7) or adali-
mumab (n = 14) treatment due to inefficacy. Antibody
data were missing for one adalimumab patient. Antibo-
dies against infliximab and adalimumab were detected
i n5o f7( 7 1 % )a n di n8o f1 3( 6 2 % )p a t i e n t sw h od i s -
continued treatment due to inefficacy, respectively. In
total, 5 of 13 (38%) patients with antibodies to TNF-a
blocking agents were primary non-responders and 8 of
13 (62%) patients were secondary non-responders.
The one-year and two-year TNF-a blocking therapy
survival rates were 71% and 66%, respectively. No signif-
icant differences were found in one-year or two-year
survival rates between the three TNF-a blocking agents
(P = 0.593 and P = 0.127, respectively) (Table 2).
Results of univariate and multivariate Cox regression
analysis for discontinuation of anti-TNF-a treatment are
presented in Table 5. Since female gender (HR: 0.503)
and absence of peripheral arthritis (HR: 0.382) were sig-
nificantly associated with treatment discontinuation in
univariate Cox regression analysis, baseline variables
that significantly differed between men and women (age,
patient’sG D A ,E S R ,c h e s te x p a n s i o n ,a n do c c i p u tt o
wall distance) or between patients with and without per-
ipheral arthritis (BASDAI, ASDAS, physician’sG D A ,
and CRP) were included in multivariate analysis. Multi-
variate Cox regression analysis showed that female gen-
der (HR: 0.406), absence of peripheral arthritis (HR:
0.320), higher BASDAI score (HR: 1.225), and lower
ESR level (HR: 0.983) or alternatively, lower CRP level
(HR: 0.984), were independent baseline predictors of
discontinuation of anti-TNF-a treatment (Table 5).
Discussion
In this prospective longitudinal observational cohort
study, ASAS20 and ASAS40 response was reached by
51% to 80% and 38% to 63% of AS patients at three to
six months of anti-TNF-a treatment, respectively. These
results from daily practice are in line with the findings
in RCTs [1-3]. Although TNF-a blocking therapy is
effective in the majority of AS patients, identifying
patients who are likely to benefit from TNF-a blocking
therapy is important, especially in view of the potential
side effects and financial burden of these agents. Data
from observational studies are necessary, since inclusion
criteria of RCTs are very strict and, therefore, not
Table 2 Response and drug survival rate in AS patients treated with TNF-a blocking therapy
Total IFX ETA ADA
Number of patients 220 32 137 51
ASAS20 responders at three months 68% 80% 66% 65%
(number of patients) (145 of 214) (24 of 30) (88 of 133) (33 of 51)
ASAS20 responders at six months 63% 71% 66% 51%
(number of patients) (132 of 209) (22 of 31) (86 of 131) (24 of 47)
ASAS40 responders at three months 49% 63% 47% 45%
(number of patients) (104 of 214) (19 of 30) (62 of 133) (23 of 51)
ASAS40 responders at six months 46% 52% 48% 38%
(number of patients) (97 of 209) (16 of 31) (63 of 131) (18 of 47)
BASDAI50 responders at three months 49% 60% 46% 51%
(number of patients) (105 of 214) (18 of 30) (61 of 133) (26 of 51)
BASDAI50 responders at six months 50% 48% 51% 47%
(number of patients) (104 of 209) (15 of 31) (67 of 131) (22 of 47)
One-year drug survival 71% 76% 72% 65%
(number of patients) (136 of 192) (22 of 29) (88 of 123) (26 of 40)
Two-year drug survival 66% 70% 69% 48%
(number of patients) (97 of 148) (19 of 27) (66 of 96) (12 of 25)
See Table 1 for definitions.
No statistical differences were found between treatment groups (P ≥0.05).
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a blocking therapy in daily clinical practice. Our finding
that younger AS patients respond significantly better to
anti-TNF-a treatment is in line with previous studies
using data from RCTs and population based registries
[5-7]. Previous studies in rheumatoid arthritis (RA) also
found that females were less likely to achieve remission
on anti-TNF-a treatment [19,20]. Furthermore, female
gender was significantly associated with discontinuation
of TNF-a blocking therapy in registries of arthritic
rheumatic diseases [21,22] and AS [7,9]. Unfortunately,
it is still unclear why male patients respond better to
TNF-a blocking therapy.
Multiple studies have shown the importance of raised
inflammatory markers with regard to achieving clinical
response [4-7] or treatment continuation [7]. This study
also confirms the predictive value of high ESR or CRP
levels. Our finding that absence of peripheral arthritis is
associated with treatment discontinuation is in
accordance with Kristensen et al., who reported that
patients with peripheral arthritis are more likely to con-
tinue TNF-a blocking therapy [9]. In the present study,
presence of peripheral arthritis was also independently
related to ASAS20 and BASDAI50 response at six
months in the presence of age and gender, indicating
that concomitant peripheral arthritis is a predictor of
both response and continuation of anti-TNF-a
treatment.
Recently, the ASDAS has been developed to assess a
broader spectrum of disease activity [10,11]. A new and
interesting finding is that higher ASDAS score was iden-
tified as a significant baseline predictor of ASAS20 and
ASAS40 response to TNF-a blocking therapy in this
study. Until now, in clinical practice, starting and conti-
nuation TNF-a blocking therapy is mainly based on
BASDAI response, which is solely based on the opinion
of the patient. In this study, more objective variables
such as higher inflammatory markers and higher
Table 3 Baseline predictors of ASAS20 response at three months of anti-TNF-a treatment
Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Age (yr)†
a 0.982 (0.959 to 1.006) 0.150 0.972 (0.947 to 0.998) 0.035
Gender Female 1 - -
Male 2.166 (1.185 to 3.958) 0.012 3.151 (1.580 to 6.285) 0.001
Duration of symptoms (yr)† 1.001 (0.976 to 1.028) 0.914 ***
HLA-B27 Negative 1 - -
Positive 0.779 (0.363 to 1.675) 0.523 ***
Peripheral arthritis Absent 1 - -
Present 2.120 (0.876 to 5.129) 0.096 **
BASDAI (range 0 to 10)‡ 0.946 (0.793 to 1.129) 0.538 ***
ASDAS‡ 1.458 (0.992 to 2.144) 0.055 *
Physician’s GDA (range 0 to 10)‡ 1.122 (0.983 to 1.282) 0.089 **
Patient’s GDA (range 0 to 10)‡
a 1.029 (0.882 to 1.201) 0.714 **
ESR (mm/h)‡
a 1.016 (1.000 to 1.032) 0.049 1.023 (1.005 to 1.041) 0.014
CRP (mg/l)‡ 1.021 (1.003 to 1.040) 0.025 *
BASFI (range 0 to 10)‡ 0.939 (0.816 to 1.081) 0.382 ***
Chest expansion (cm)‡
a 1.081 (0.948 to 1.233) 0.243 **
Modified Schober test (cm)‡ 1.026 (0.861 to 1.224) 0.773 ***
Occiput to wall distance (cm)‡
a 0.981 (0.942 to 1.022) 0.364 **
Lateral lumbar flexion L (cm)‡ 1.027 (0.965 to 1.092) 0.402 ***
Lateral lumbar flexion R (cm)‡ 1.029 (0.968 to 1.094) 0.352 ***
TNF-a blocking agent ETA 1 - -
IFX 2.045 (0.780 to 5.364) 0.146 **
ADA 0.938 (0.476 to 1.846) 0.852 **
See Table 1 for definitions.
OR refers to the risk of achieving ASAS20 response: † per year; ‡ per 1 grade or 1 point.
a Significant difference (P < 0.05) between men and women at baseline.
* CRP and ASDAS were not selected during forward conditional logistic regression due to the strong correlation with ESR (ESR and CRP: r = 0.669, P = 0.000; ESR
and ASDAS: r = 0.412, P = 0.000). Although, higher CRP level (OR: 1.024, 95% CI: 1.004 to 1.044) and higher ASDAS level (OR: 1.728, 95% CI: 1.126 to 2.652) were
also significant predictors of ASAS20 response at three months in the presence of age and gender.
** The variable was not selected during multivariate regression analysis (P ≥0.05).
*** The variable was not tested in multivariate regression analysis because of a P-value > 0.3 in univariate regression analysis and no significant difference
between men and women at baseline.
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Page 6 of 10ASDAS score were identified as independent baseline
predictors of response and/or continuation of anti-TNF-
a treatment. In contrast, a higher baseline BASDAI
score was independently associated with treatment dis-
continuation. Based on these results, it seems clinically
relevant to include more objective variables in the eva-
luation of anti-TNF-a treatment.
Our finding that the majority of AS patients discontin-
ued TNF-a blocking therapy because of inefficacy is in
accordance with Glintborg et al. [7], but other registries
found an almost equal distribution between treatment
withdrawal due to adverse events and inefficacy [9,23]
or even a higher discontinuation rate because of adverse
events [21,22]. These differences may be explained by
variation in the classification of reasons for stopping
TNF-a blocking therapy.
Since previous studies in AS patients treated with eta-
nercept have reported that no antibodies against
etanercept could be detected [24,25], antibodies were
only measured in patients who discontinued infliximab
and adalimumab due to inefficacy in this study. Antibody
formation seems to be related to inefficacy of infliximab
and adalimumab since these antibodies were detected in
almost two third of patients (13 out of 20) who discontin-
ued infliximab or adalimumab treatment due to ineffi-
cacy. This is in line with our previous findings in a
smaller group of AS patients. In this study, patients with
antibodies had significantly lower serum TNF-a blocker
levels compared to patients without antibodies and sig-
nificant negative correlations between serum levels of
TNF-a blocking agents and assessments of disease activ-
ity were found [24]. Based on these results, it seems use-
ful to determine antibody formation to TNF-a blocking
agents in non-responsive AS patients.
In the present study, we did not find significant differ-
ences in the percentage of ASAS20, ASAS40, or
Table 4 Baseline predictors of ASAS20 response at six months of anti-TNF-a treatment
Univariate analysis Multivariate analysis
OR (95% CI) P-value OR (95% CI) P-value
Age (yr)†
a 0.977 (0.954 to 1.002) 0.069 0.960 (0.934 to 0.987) 0.004
Gender Female 1 - -
Male 1.995 (1.087 to 3.659) 0.026 2.991 (1.519 to 5.890) 0.002
Duration of symptoms (yr)† 0.997 (0.972 to 1.023) 0.821 ***
HLA-B27 Negative 1 - -
Positive 1.086 (0.520 to 2.266) 0.827 ***
Peripheral arthritis Absent 1 - -
Present 2.218 (0.952 to 5.165) 0.065 *
BASDAI (range 0 to 10)‡ 1.031 (0.873 to 1.219) 0.717 ***
ASDAS‡ 1.356 (0.945 to 1.946) 0.099 1.573 (1.051 to 2.354) 0.028
Physician’s GDA (range 0 to 10)‡ 1.087 (0.955 to 1.239) 0.207 **
Patient’s GDA (range 0 to 10)‡
a 1.124 (0.973 to 1.300) 0.113 *
ESR (mm/h)‡
a 1.005 (0.991 to 1.019) 0.499 **
CRP (mg/l)‡ 1.009 (0.993 to 1.024) 0.281 **
BASFI (range 0 to 10)‡ 0.989 (0.861 to 1.135) 0.872 ***
Chest expansion (cm)‡
a 1.108 (0.953 to 1.289) 0.183 **
Modified Schober test (cm)‡ 0.900 (0.755 to 1.074) 0.243 **
Occiput to wall distance (cm)‡
a 0.989 (0.950 to 1.030) 0.591 **
Lateral lumbar flexion L (cm)‡ 0.985 (0.928 to 1.044) 0.606 ***
Lateral lumbar flexion R (cm)‡ 1.018 (0.960 to 1.079) 0.557 ***
TNF-a blocking agent ETA 1 - -
IFX 1.279 (0.544 to 3.008) 0.573 **
ADA 0.546 (0.278 to 1.076) 0.079 **
See Table 1 for definitions.
OR refers to the risk of achieving ASAS20 response: † per year; ‡ per 1 grade or 1 point.
a Significant difference (P < 0.05) between men and women at baseline.
* Presence of peripheral arthritis and patient’s GDA were not selected during forward conditional logistic regression due to the significant difference in ASDAS
score between patients with and without peripheral arthritis (mean 4.2 vs. 3.7, P = 0.001) and the strong correlation between ASDAS and patient’s GDA (r =
0.508, P = 0.000). Although, presence of peripheral arthritis (OR: 2.518, 95% CI: 1.053 to 6.025) and higher patient’s GDA (OR: 1.173, 95% CI: 1.003 to 1.372) were
also significant predictors of ASAS20 response at 6 months in the presence of age and gender.
** The variable was not selected during multivariate regression analysis (P ≥0.05).
*** The variable was not tested in multivariate regression analysis because of a P-value > 0.3 in univariate regression analysis and no significant difference
between men and women at baseline.
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one-year and two-year drug survival rates between the
three TNF-a blocking agents. Furthermore, the type of
anti-TNF-a treatment (infliximab, etanercept, or adali-
mumab) was not significantly associated with achieving
response or discontinuation of treatment. However,
these findings should be interpreted with caution since
there were differences in disease duration, the percen-
tage of patients with extra-articular manifestations, phy-
sician’s GDA, and spinal mobility measures at baseline
and there was an uneven distribution of patients among
the different treatment groups.
Conclusions
This prospective longitudinal observational cohort study
identified higher ASDAS score, higher ESR or CRP
level, presence of peripheral arthritis, younger age, male
gender, lower modified Schober test, higher patient’s
GDA, and lower BASDAI as independent baseline pre-
dictors of response and/or continuation of TNF-a
blocking therapy in AS patients. These findings may
help clinicians to identify AS patients who are more
likely to benefit from TNF-a blocking therapy in daily
clinical practice.
Abbrevations
AS: Ankylosing Spondylitis; ASAS: Assessments in
Ankylosing Spondylitis; ASDAS: Ankylosing Spondylitis
Disease Activity Score; BASDAI: Bath Ankylosing Spon-
dylitis Disease Activity Index; BASFI: Bath Ankylosing
Spondylitis Functional Index;C R P :C - r e a c t i v ep r o t e i n ;
ESR: erythrocyte sedimentation rate; GDA: global dis-
ease activity; HR: hazard ratio; IBD: inflammatory bowel
disease; MCL: Medical Center Leeuwarden; OR: odds
ratio; RA: rheumatoid arthritis; RCTs: randomized con-
trolled trials; RIA: radioimmunoassay; TNF-a:t u m o r
Table 5 Baseline predictors of anti-TNF-a treatment discontinuation
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age (yr)†
a 0.994 (0.975 to 1.014) 0.561 **
Gender Female 1 - -
Male 0.503 (0.321 to 0.787) 0.003 0.406 (0.251 to 0.657) 0.000
Duration of symptoms (yr)† 0.981 (0.959 to 1.002) 0.082 **
HLA-B27 Negative 1 - -
Positive 0.823 (0.468 to 1.448) 0.500 ***
Peripheral arthritis Absent 1 - -
Present 0.382 (0.176 to 0.830) 0.015 0.320 (0.144 to 0.712) 0.005
BASDAI (range 0 to 10)‡
b 1.162 (1.016 to 1.329) 0.028 1.225 (1.053 to 1.424) 0.008
ASDAS‡
b 1.005 (0.759 to 1.330) 0.974 **
Physician’s GDA (range 0 to 10)‡
b 0.907 (0.816 to 1.008) 0.070 **
Patient’s GDA (range 0 to 10)‡
a 1.075 (0.958 to 1.208) 0.219 **
ESR (mm/h)‡
a 0.987 (0.974 to 0.999) 0.039 0.983 (0.969 to 0.997) 0.018
CRP (mg/l)‡
b 0.986 (0.972 to 1.000) 0.049 *
BASFI (range 0 to 10)‡ 1.045 (0.935 to 1.168) 0.438 ***
Chest expansion (cm)‡
a 0.986 (0.903 to 1.076) 0.753 **
Modified Schober test (cm)‡ 1.189 (1.036 to 1.365) 0.014 **
Occiput to wall distance (cm)‡
a 0.971 (0.938 to 1.006) 0.971 **
Lateral lumbar flexion L (cm)‡ 1.018 (0.973 to 1.066) 0.434 ***
Lateral lumbar flexion R (cm)‡ 1.016 (0.971 to 1.062) 0.498 ***
TNF-a blocking agent ETA 1 - -
IFX 0.847 (0.441 to 1.627) 0.618 ***
ADA 1.334 (0.769 to 2.314) 0.305 ***
See Table 1 for definitions.
HR refers to the risk of anti-TNF-a treatment discontinuation: † per year; ‡ per 1 grade or 1 point.
a Significant difference (P < 0.05) between men and women at baseline.
b Significant difference (P < 0.05) between patients with peripheral arthritis (defined as at least one swollen joint) and only axial disease at baseline.
* CRP was not selected during forward conditional logistic regression due to the strong correlation with ESR (r = 0.669, P = 0.000) and the significant difference
in CRP level between patients with and without peripheral arthritis (median 17 vs. 12, P = 0.014). Although, lower CRP level (HR: 0.984, 95% CI: 0.969 to 0.999)
was also a significant predictor of treatment discontinuation in the presence of gender and BASDAI.
** The variable was not selected during multivariate regression analysis (P ≥0.05).
*** The variable was not tested in multivariate regression analysis because of a P-value > 0.3 in univariate regression analysis and no significant difference
between men and women at baseline.
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Page 8 of 10necrosis factor alpha; UMCG: University Medical Center
Groningen; VAS: visual analogue scale.
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